USD 7.03 billion
Global Pulmonary Arterial Hypertension Market Size, Share, Growth Analysis, By Route of Administration(Oral, Intravenous), By Type(Branded and Generic) - Industry Forecast 2024-2031
Report ID:
SQMIG35H2222 |
Region:
Global |
Published Date: February, 2024
Pages:
157
|
Tables:
61 |
Figures:
77
Global Pulmonary Arterial Hypertension Market Insights
Pulmonary Arterial Hypertension Market size was valued at USD 7.03 billion in 2021 and is poised to grow from USD 7.40 billion in 2022 to USD 10.65 billion by 2030, at a CAGR of 5.33% during the forecast period (2023-2030).
The primary drivers of the pulmonary arterial hypertension market expansion are the rising prevalence of the disease, government funding for the discovery of orphan medications, and the rising geriatric population.
According to a study titled "Prevalence, incidence, and survival of pulmonary arterial hypertension: A systematic review for the global burden of disease 2020 study" that was released in January 2022, pulmonary arterial hypertension (PAH) is characterised by increased resistance in the pulmonary arterioles as a result of remodelled blood vessels. The prevalence varied between 0.4% and 1.4% per 100,000 people. A global estimate of 1.28 billion persons aged 30-79 have hypertension, with the majority (two-thirds) residing in low- and middle-income countries, according to World Health Organisation (WHO) important facts published in August 2021. Among the international goals for non-communicable diseases is to decrease about 33% between 2010 and 2030, the prevalence of hypertension.
US Pulmonary Arterial Hypertension Market is poised to grow at a sustainable CAGR for the next forecast year.
Market snapshot - 2024-2031
Global Market Size
Largest Segment
Branded
Fastest Growth
Branded
Growth Rate
5.33% CAGR
Global Pulmonary Arterial Hypertension Market 2022-2030 ($ Bn)
Country Share for North America Region- 2022 (%)
Global Pulmonary Arterial Hypertension Market Size By Type 2022-2030 ($ Bn)
Global Pulmonary Arterial Hypertension Market Size By Type 2022-2030 (%)
To get more reports on the above market click here to Buy The Report
Global Pulmonary Arterial Hypertension Market Segmental Analysis
Global Pulmonary Arterial Hypertension Market is segmented on the basis of, type, route of administration, drug class and region. By type, the market is segmented into branded and generics. By route of administration, market is segmented into oral, intravenous, inhalational. By drug class, the market is segmented into endothelin receptor antagonists, pde-5 inhibitors, prostacyclin & prostacyclin analogs, sgc stimulators. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Pulmonary Arterial Hypertension Market Analysis by Drug Class
In 2022, the prostacyclin and prostacyclin analogues category dominated the market and held a 45.0% revenue share. High demand and expanding indications are two important elements that have contributed to the big share. Uptravi, a product in the Prostacyclin and Prostacyclin Analogues category, was given FDA approval in July 2021 for intravenous use in patients with pulmonary arterial hypertension.
The SGC simulators market is anticipated to expand at a CAGR of over 5%. By amplifying NO-SGC signaling, SGC stimulators can ensure that the SGC is fully activated. The sole medication in this class licensed for PAH is riociguat (Adempas from Bayer). Sales of Adempas increased by over 50% in 2020 compared to 2019, showing strong demand.
Pulmonary Arterial Hypertension Market Analysis by Route of Administration
In 2022, the oral segment dominated the market and accounted for more than 50.0% of total revenue. This is because patients prefer the oral method of administration and oral formulations for pulmonary arterial hypertension are becoming more widely available. Oral PAH medications include Letairis, Opsumit, Adcirca, and Revatio, to name a few. For instance, Johnson & Johnson sold 1.6 billion USD worth of Opsumit tablets in 2021. Compared to 2019, the sales reflected a year-over-year gain of 23.5%. Other reasons influencing the adoption of oral medication administration include patient safety, affordability, high efficacy, and quick drug delivery.
The segment for intravenous/subcutaneous injections is predicted to grow at the quickest rate, exceeding 5.0% during the forecast period, as a result of rising indications and regulatory agency approvals as well as technological advancements in drug delivery methods that aim to improve patient compliance. A subcutaneous pump called Remunity was introduced by United Therapeutics in February 2021 to provide prefilled cassettes of Remodulin to PAH patients. Because of its small size and features like wireless remote programming and water resistance, the product offers a significant improvement over existing subcutaneous pumps.
Global Pulmonary Arterial Hypertension Market Size By Type 2022(%), 2023 (%)
To get detailed analysis on other segments, Request For Free Sample Report
Global Pulmonary Arterial Hypertension Market Regional Insights
In 2022, North America held the biggest revenue share of over 40.0% in the market for pulmonary arterial hypertension. The sophisticated healthcare systems in the United States and Canada, which make it easier to get cutting-edge treatments, are to blame for the significant portion. Additionally, heightened awareness, a high prevalence of diagnoses, and favorable government measures assist the expansion of the business in this area. The rise of the local market is aided by the presence of significant companies and a carefully thought-out reimbursement system. The demand for advanced healthcare facilities for treating pulmonary arterial hypertension in the region is being driven by the increased prevalence of chronic and infectious diseases and the high diagnostic rate
Over the following few years, the Asia Pacific market is anticipated to have a CAGR of more than 6.0%. This is due to the rising generic drug usage, the existence of important pharmaceutical businesses, and the evolving healthcare infrastructure. For instance, the generic version of Gilead Sciences' Letairis, Ambrisentan Tablets, were approved by the U.S. FDA in April 2021 for Cipla, an Indian pharmaceutical company. The portfolio of the business was improved by this. Additionally, the need for better healthcare systems in the area is being fueled by the region's enormous population base and the rising incidence of diseases
Global Pulmonary Arterial Hypertension Market Size By Geography, 2022-2030, 2024-2031
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Global Pulmonary Arterial Hypertension Market Dynamics
Pulmonary Arterial Hypertension Market Drivers
Increasing Prevalence of Pulmonary Arterial Hypertension to Bolster Market Growth
- A uncommon, progressive condition known as pulmonary arterial hypertension (PAH) is characterised by elevated blood pressure in the arteries that carry blood to the lungs. Globally, the prevalence of PAH is rising as a result of ageing populations, rising rates of risk factors like obesity, and improved diagnostic techniques. This is anticipated to increase demand for PAH remedies.
- The creation of novel PAH treatments, such as prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase inhibitors, has advanced significantly. Demand has increased as a result of these medicines' improving effectiveness and safety characteristics.
Pulmonary Arterial Hypertension Market Restraints
Limited Patient Pool might Pose as a Threat
- PAH is a rare disease, and the prevalence of the disease is relatively low compared to other chronic diseases. As a result, the patient pool for PAH is limited, which can impact the commercial viability of PAH drugs and discourage investment in drug development. The diagnosis involves several tests, including echocardiography, right heart catheterization, and pulmonary function tests. Additionally, the symptoms of PAH, such as shortness of breath and fatigue, can be non-specific and may be attributed to other conditions, leading to misdiagnosis or delayed diagnosis.
Request Free Customization of this report to help us to meet your business objectives.
Global Pulmonary Arterial Hypertension Market Competitive Landscape
The market for pulmonary arterial hypertension is dominated by a small number of companies in terms of branded or patented medications. Gilead Sciences, Johnson & Johnson, United Therapeutics, and other companies are among them. To counter this, numerous pharmaceutical firms are launching generic versions of pulmonary arterial hypertension medications in an effort to enter the PAH market as a result of the increased number of patent expirations.
Pulmonary Arterial Hypertension Market Top Player’s Company Profiles
- GlaxoSmithKline plc (United Kingdom)
- Gilead Sciences, Inc. (United States)
- Pfizer, Inc. (United States)
- Arena Pharmaceuticals, Inc. (United States)
- Reata Pharmaceuticals, Inc. (United States)
- SteadyMed Therapeutics, Inc. (United States)
- Lung Biotechnology PBC (United States)
- AstraZeneca plc (United Kingdom)
- Bristol-Myers Squibb Company (United States)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Liquidia Technologies, Inc. (United States)
- Merck & Co., Inc. (United States)
- Novartis AG (Switzerland)
- Actelion Pharmaceuticals US, Inc. (United States)
- Acceleron Pharma Inc. (United States)
- Eli Lilly and Company (United States)
- Bayer HealthCare Pharmaceuticals (United States)
- Mallinckrodt Pharmaceuticals (United Kingdom)
- Aadi Bioscience, Inc. (United States)
Pulmonary Arterial Hypertension Market Recent Developments
- In July 2022, Cereno Scientific revealed that the first patient had begun the Phase II research for pulmonary arterial hypertension (PAH) using the medication candidate CS1.
- In June 2022, Seralutinib may be used to treat pulmonary arterial hypertension (PAH), according to crucial preclinical results published, according to a press release from Gossamer Bio, Inc.
Global Pulmonary Arterial Hypertension Key Market Trends
- With advancements in technology and an improved understanding of the genetic basis of PAH, there is an increasing focus on developing personalized therapies for patients. Companies are investing in research and development to identify biomarkers that can be used to predict disease progression and response to treatment, and to develop therapies that target specific genetic mutations.
Global Pulmonary Arterial Hypertension Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates and Analyses the Data collected by means of Primary Exploratory Research backed by the robust Secondary Desk research.
According to our analyses, the global pulmonary arterial hypertension (PAH) market is a growing and dynamic market, driven by a combination of factors such as increasing prevalence of the disease, rising awareness, improving diagnosis and treatment options, and growing investment in research and development. Despite several challenges, such as limited patient pool and high cost of therapies, the market is expected to grow significantly in the coming years. Another key driver of the market is the growing investment in research and development. Companies are investing in developing new therapies that offer improved efficacy, reduced side effects, and greater convenience for patients. This is expected to drive growth in the market as patients and healthcare providers seek out more effective treatment options. The global PAH market is a growing and dynamic market, driven by a combination of factors such as increasing prevalence, growing investment in research and development, and rising awareness..
| Report Metric | Details |
|---|---|
| Market size value in 2023 | USD 7.03 billion |
| Market size value in 2031 | USD 10.65 billion |
| Growth Rate | 5.33% |
| Forecast period | 2024-2031 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Global Pulmonary Arterial Hypertension Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Global Pulmonary Arterial Hypertension Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Global Pulmonary Arterial Hypertension Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Global Pulmonary Arterial Hypertension Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Global Pulmonary Arterial Hypertension Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Global Pulmonary Arterial Hypertension Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Global Pulmonary Arterial Hypertension Market Report Snapshots
Want to customize this report?
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATION
USA (+1) 351-333-4748
